Brief: Essa Pharma Announces Clinical Collaboration With Astellas

ESSA Pharma

25/02/2021 12:16

Feb 25 (Reuters) - ESSA Pharma Inc  EPIX.O :
    * ESSA PHARMA ANNOUNCES CLINICAL COLLABORATION WITH ASTELLAS
TO
EVALUATE THE COMBINATION OF EPI-7386 AND ENZALUTAMIDE FOR
PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    * ESSA PHARMA- CO TO SPONSOR & CONDUCT PHASE 1/2 STUDY TO
EVALUATE
SAFETY, TOLERABILITY & PRELIMINARY EFFICACY OF COMBINATION OF
EPI-7386 & ENZALUTAMIDE
    * ESSA PHARMA - PHASE 1/2 STUDY TO BE COMNDUCTED IN MCRPC
PATIENTS
WHO HAVE NOT YET BEEN TREATED WITH SECOND-GENERATION
ANTIANDROGEN THERAPIES
    * ESSA PHARMA INC - ASTELLAS WILL SUPPLY ENZALUTAMIDE FOR
TRIAL
    * ESSA PHARMA INC - ESSA WILL RETAIN ALL RIGHTS TO EPI-7386
    * ESSA PHARMA INC - PHASE 1/2 STUDY FOR COMBINATION OF
EPI-7386 &
ENZALUTAMIDE EXPECTED TO START IN 2021

Source text for Eikon:  ID:nPn2MhsnYa 
Further company coverage:  EPIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))